In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles

Table 1 NANO-ASODNs inhibit growth of HCC in vivo

Group (mg/kg)	Tumor volume (mm3)	Tumor weight (g)	Tumor inhibition (%)	AFP (ng/mL)
Control (PBS)	1633.38 ± 525.93	1.92 ± 0.45	-	457.63 ± 141.47
ASODN-100	321.56 ± 85.55b	0.57 ± 0.16b	70.31	97.63 ± 23.79b
ASODN-50	509.29 ± 300.85b	0.73 ± 0.22b	61.98	179.86 ± 210.27b
ASODN-25	835.25 ± 263.33a	1.14 ± 0.12b	40.63	428.63 ± 141.47
5-FU10	717.19 ± 281.25b	0.98 ± 0.16b	48.96	315.25 ± 195.77
Nano-ASODN-100	225.81 ± 128.75b	0.35 ± 0.17b	81.77	58.25 ± 30.83b
Nano-ASODN-50	457.88 ± 249.29b	0.52 ± 0.21b	72.92	89.38 ± 61.75b
Nano-ASODN-25	584.00 ± 261.92b	0.83 ± 0.20b	56.77	205.38 ± 125.16b
Nano control	1319.25 ± 340.70	1.59 ± 0.18	17.18	419.25 ± 148.46

^aP < 0.05,

^bP < 0.01 vs control (PBS).